BeLiver originated at the confluence of pioneering research from the Bordeaux University Hospital (CHU) and the INSERM/CNRS research unit BRIC (Bordeaux Institute Of Oncology - UMR1312/US5).

Our founders recognized the critical challenge of treatment heterogeneity in cancer – where patients with seemingly similar diagnoses respond vastly differently to therapies. This inspired our mission: to forge a new path with a rational, enlightened therapeutic decision tool.

We translate complex proteomic data and the power of artificial intelligence into clear, actionable predictions, aiming to ensure each patient receives the optimal treatment pathway from day one.